Cypherpunk Technologies Inc. (CYPH): Total Liabilities
$9.68M
As of 2025-12-31
$3.65M
As of 2026-06-30
-5.6%
3-year compound annual growth
+4.6%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.68M | -31.3% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $14.08M | +11.0% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $12.68M | +10.4% | 2024-03-18, Balance as of period end |
| 2022-12-31 | $11.49M | +14.6% | 2024-03-18, Balance as of period end |
| 2021-12-31 | $10.02M | +29.8% | 2023-03-24, Balance as of period end |
| 2020-12-31 | $7.72M | -16.1% | 2022-03-11, Balance as of period end |
| 2019-12-31 | $9.20M | -7.1% | 2021-03-12, Balance as of period end |
| 2018-12-31 | $9.90M | -44.8% | 2020-03-16, Balance as of period end |
| 2017-12-31 | $17.95M | -50.4% | 2019-04-01, Balance as of period end |
| 2016-12-31 | $36.16M | n/a | 2018-02-23, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Cypherpunk Technologies Inc. (CYPH) | 2025-12-31 | $9.68M | -31.3% |
| Transcode Therapeutics, Inc. (RNAZ) | 2025-12-31 | $10.52M | +12.9% |
| Apimeds Pharmaceuticals US, Inc. (APUS) | 2025-12-31 | $10.84M | +690.3% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $57.38M | -11.4% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $194.09M | +20.1% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $23.85M | -11.7% |
| Climb Bio, Inc. (CLYM) | 2025-12-31 | $7.27M | +37.0% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | 2025-12-31 | $20.69M | +53.8% |
| Eledon Pharmaceuticals, Inc. (ELDN) | 2025-12-31 | $32.23M | -45.6% |
Compare CYPH, RNAZ, APUS, ACRS side by side · Screen every company in Pharmaceutical Preparations ↗